Literature DB >> 19357165

Regulation of Vif mRNA splicing by human immunodeficiency virus type 1 requires 5' splice site D2 and an exonic splicing enhancer to counteract cellular restriction factor APOBEC3G.

Dibyakanti Mandal1, Colin M Exline, Zehua Feng, C Martin Stoltzfus.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) accessory protein Vif is encoded by an incompletely spliced mRNA resulting from splicing of the major splice donor in the HIV-1 genome, 5' splice site (5'ss) D1, to the first splice acceptor, 3'ss A1. We have shown previously that splicing of HIV-1 vif mRNA is tightly regulated by suboptimal 5'ss D2, which is 50 nucleotides downstream of 3'ss A1; a GGGG silencer motif proximal to 5'ss D2; and an SRp75-dependent exonic splicing enhancer (ESEVif). In agreement with the exon definition hypothesis, mutations within 5'ss D2 that are predicted to increase or decrease U1 snRNP binding affinity increase or decrease the usage of 3'ss A1 (D2-up and D2-down mutants, respectively). In this report, the importance of 5'ss D2 and ESEVif for avoiding restriction of HIV-1 by APOBEC3G (A3G) was determined by testing the infectivities of a panel of mutant viruses expressing different levels of Vif. The replication of D2-down and ESEVif mutants in permissive CEM-SS cells was not significantly different from that of wild-type HIV-1. Mutants that expressed Vif in 293T cells at levels greater than 10% of that of the wild type replicated similarly to the wild type in H9 cells, and Vif levels as low as 4% were affected only modestly in H9 cells. This is in contrast to Vif-deleted HIV-1, whose replication in H9 cells was completely inhibited. To test whether elevated levels of A3G inhibit replication of D2-down and ESEVif mutants relative to wild-type virus replication, a Tet-off Jurkat T-cell line that expressed approximately 15-fold-higher levels of A3G than control Tet-off cells was generated. Under these conditions, the fitness of all D2-down mutant viruses was reduced relative to that of wild-type HIV-1, and the extent of inhibition was correlated with the level of Vif expression. The replication of an ESEVif mutant was also inhibited only at higher levels of A3G. Thus, wild-type 5'ss D2 and ESEVif are required for production of sufficient Vif to allow efficient HIV-1 replication in cells expressing relatively high levels of A3G.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19357165      PMCID: PMC2687371          DOI: 10.1128/JVI.02231-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators.

Authors:  Reuben S Harris; Svend K Petersen-Mahrt; Michael S Neuberger
Journal:  Mol Cell       Date:  2002-11       Impact factor: 17.970

2.  Hypermutation of HIV-1 DNA in the absence of the Vif protein.

Authors:  Denise Lecossier; Francine Bouchonnet; François Clavel; Allan J Hance
Journal:  Science       Date:  2003-05-16       Impact factor: 47.728

3.  DNA deamination mediates innate immunity to retroviral infection.

Authors:  Reuben S Harris; Kate N Bishop; Ann M Sheehy; Heather M Craig; Svend K Petersen-Mahrt; Ian N Watt; Michael S Neuberger; Michael H Malim
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

4.  Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA.

Authors:  M A Khan; C Aberham; S Kao; H Akari; R Gorelick; S Bour; K Strebel
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  Human immunodeficiency virus type 1 Vif is efficiently packaged into virions during productive but not chronic infection.

Authors:  Sandra Kao; Hirofumi Akari; Mohammad A Khan; Markus Dettenhofer; Xiao-Fang Yu; Klaus Strebel
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

6.  The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.

Authors:  Hui Zhang; Bin Yang; Roger J Pomerantz; Chune Zhang; Shyamala C Arunachalam; Ling Gao
Journal:  Nature       Date:  2003-05-28       Impact factor: 49.962

7.  Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.

Authors:  Bastien Mangeat; Priscilla Turelli; Gersende Caron; Marc Friedli; Luc Perrin; Didier Trono
Journal:  Nature       Date:  2003-05-28       Impact factor: 49.962

8.  HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.

Authors:  Mariana Marin; Kristine M Rose; Susan L Kozak; David Kabat
Journal:  Nat Med       Date:  2003-10-05       Impact factor: 53.440

9.  The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.

Authors:  Ann M Sheehy; Nathan C Gaddis; Michael H Malim
Journal:  Nat Med       Date:  2003-10-05       Impact factor: 53.440

10.  Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3).

Authors:  Satish K Pillai; Joseph K Wong; Jason D Barbour
Journal:  Retrovirology       Date:  2008-03-13       Impact factor: 4.602

View more
  12 in total

1.  Excessive RNA splicing and inhibition of HIV-1 replication induced by modified U1 small nuclear RNAs.

Authors:  Dibyakanti Mandal; Zehua Feng; C Martin Stoltzfus
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  Natural Single-Nucleotide Variations in the HIV-1 Genomic SA1prox Region Can Alter Viral Replication Ability by Regulating Vif Expression Levels.

Authors:  Masako Nomaguchi; Naoya Doi; Yosuke Sakai; Hirotaka Ode; Yasumasa Iwatani; Takamasa Ueno; Yui Matsumoto; Yasuyuki Miyazaki; Takao Masuda; Akio Adachi
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

3.  Tra2-mediated recognition of HIV-1 5' splice site D3 as a key factor in the processing of vpr mRNA.

Authors:  Steffen Erkelenz; Gereon Poschmann; Stephan Theiss; Anja Stefanski; Frank Hillebrand; Marianne Otte; Kai Stühler; Heiner Schaal
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

4.  Characterizing HIV-1 Splicing by Using Next-Generation Sequencing.

Authors:  Ann Emery; Shuntai Zhou; Elizabeth Pollom; Ronald Swanstrom
Journal:  J Virol       Date:  2017-02-28       Impact factor: 5.103

5.  Serine- and arginine-rich proteins 55 and 75 (SRp55 and SRp75) induce production of HIV-1 vpr mRNA by inhibiting the 5'-splice site of exon 3.

Authors:  Anna Tranell; Eva Maria Fenyö; Stefan Schwartz
Journal:  J Biol Chem       Date:  2010-08-04       Impact factor: 5.157

6.  An intronic G run within HIV-1 intron 2 is critical for splicing regulation of vif mRNA.

Authors:  Marek Widera; Steffen Erkelenz; Frank Hillebrand; Aikaterini Krikoni; Darius Widera; Wolfgang Kaisers; René Deenen; Michael Gombert; Rafael Dellen; Tanya Pfeiffer; Barbara Kaltschmidt; Carsten Münk; Valerie Bosch; Karl Köhrer; Heiner Schaal
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

7.  Production of HIV-1 vif mRNA Is Modulated by Natural Nucleotide Variations and SLSA1 RNA Structure in SA1D2prox Genomic Region.

Authors:  Masako Nomaguchi; Naoya Doi; Tomoya Yoshida; Takaaki Koma; Shun Adachi; Hirotaka Ode; Yasumasa Iwatani; Masaru Yokoyama; Hironori Sato; Akio Adachi
Journal:  Front Microbiol       Date:  2017-12-18       Impact factor: 5.640

8.  Expression Level of HIV-1 Vif Can Be Fluctuated by Natural Nucleotide Variations in the vif-Coding and Regulatory SA1D2prox Sequences of the Proviral Genome.

Authors:  Naoya Doi; Takaaki Koma; Akio Adachi; Masako Nomaguchi
Journal:  Front Microbiol       Date:  2019-11-28       Impact factor: 5.640

9.  Comparison of SIV and HIV-1 genomic RNA structures reveals impact of sequence evolution on conserved and non-conserved structural motifs.

Authors:  Elizabeth Pollom; Kristen K Dang; E Lake Potter; Robert J Gorelick; Christina L Burch; Kevin M Weeks; Ronald Swanstrom
Journal:  PLoS Pathog       Date:  2013-04-04       Impact factor: 6.823

10.  Global synonymous mutagenesis identifies cis-acting RNA elements that regulate HIV-1 splicing and replication.

Authors:  Matthew A Takata; Steven J Soll; Ann Emery; Daniel Blanco-Melo; Ronald Swanstrom; Paul D Bieniasz
Journal:  PLoS Pathog       Date:  2018-01-29       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.